Amadorins small-molecule platform
preclinicalplatform · medium · Thu May 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Develop proprietary small molecules for neurodegenerative diseases associated with aging, including central and peripheral nervous system indications.
Proprietary Amadorin small-molecule chemistry platform producing drug candidates such as PTG-630.
Amadorins were reported to demonstrate neuroprotection across multiple preclinical models of aging-related neurodegenerative disease.
Reported neuroprotection in central and peripheral nervous system models, including Alzheimer's disease and diabetic peripheral neuropathy models.
PTG-630 for Alzheimer's disease
preclinicaldrug program · medium · Thu May 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Prevent or slow progression of Alzheimer's disease by providing neuroprotection in aging-related neurodegenerative disease.
Oral small-molecule Amadorin drug candidate advanced through preclinical development, supported by an NIA STTR Phase 2 award.
Received a $2.5M NIA STTR Phase 2 award to advance PTG-630 toward Alzheimer's disease development; company intended to file an IND in 2023.
Reported neuroprotection in preclinical Alzheimer's disease models, with protection against mild cognitive impairment and biomarker evidence of neuronal benefit.
PTG-630 for diabetic peripheral neuropathy
preclinicaldrug program · medium · Thu May 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Treat diabetic peripheral neuropathy through neuroprotection in the peripheral nervous system.
Small-molecule Amadorin candidate tested in preclinical diabetic peripheral neuropathy models, with related NIDDK support mentioned.
Promising preclinical findings in diabetic peripheral neuropathy were cited as supporting expansion of PTG-630 to diabetic retinopathy and complementing active NIDDK awards.
Reported neuroprotection in preclinical diabetic peripheral neuropathy models.
PTG-630 for diabetic retinopathy
preclinicaldrug program · medium · Thu May 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Establish PTG-630 as a novel oral candidate for diabetic retinopathy, positioned as an alternative to injectable therapies.
Small-molecule Amadorin candidate being evaluated in preclinical proof-of-concept work for diabetic retinopathy.
Received a $0.3M NEI STTR Phase 1 award to advance PTG-630 into preclinical proof of concept in diabetic retinopathy.
